GeneDx reported a 49% increase in second-quarter revenues to $102.7 million, surpassing Wall Street estimates and marking its fourth consecutive profitable quarter. The growth was primarily driven by whole-exome and whole-genome testing, which accounted for 84% of revenues, up 69% year over year. Despite declines in hereditary cancer and other panel testing revenues, GeneDx expanded its R&D spending by 39% and improved net income to $10.8 million from a loss a year earlier. The acquisition of Fabric Genomics contributed $900,000 in Q2 revenue. The company performed 55,673 tests, with a 28% increase in whole-exome/genome tests but a drop in other panels and cancer testing volumes.